Drug Trial Radar · NCT06582524
Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3
Actual
Start
Aug 30, 2024
Primary completion
Jun 17, 2025
Study completion Jun 17, 2025
Sponsor
- Lead sponsor
- Immedica Pharma ABIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 day, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicentre study to evaluate the safety, PK, and activity (PD) of weekly subcutaneous (SC) administration of pegzilarginase in subjects with ARG1-D who are \< 24 months of age. The study consists of a screening period of up to 4 weeks, a subsequent 12-week treatment period, and a safety follow-up period of 8 weeks.
Conditions
- Arginase 1 Deficiency
Interventions
PegzilarginaseDrug
SC administration of pegzilarginase over 12 weeks in subjects with ARG1-D who are \< 24 months of age
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Plasma Arginine Concentrations in Subjects <24 Months of Age With Arginase 1 Deficiency (ARG1-D).Time frame: From baseline up to 12 weeks.
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Univ. Klinik für Kinder- und Jugendheilkunde Medizinische Universität
Graz, Austria
Unidade de Doenças Metabólicas Pediatria, Hospital Santa Maria
Lisbon, Portugal
Bradford Royal Infirmary Duckworth Lane
Bradford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.